Crinetics Pharmaceuticals Announces February 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Group 1: Stock Option and RSU Awards - Crinetics Pharmaceuticals granted non-qualified stock option awards to purchase 105,100 shares and 9,950 restricted stock unit (RSU) awards to 14 new non-executive employees under the 2021 Employment Inducement Incentive Award Plan [1][2] - The stock options have an exercise price of $36.53 per share, equal to the closing price on February 10, 2025, and will vest over four years [2] - RSUs will also vest over four years in equal annual installments, starting on the one-year anniversary of the applicable vesting commencement date [2] Group 2: Company Overview - Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on developing novel therapeutics for endocrine diseases and related tumors [3] - The lead candidate, paltusotine, is in clinical development for acromegaly and carcinoid syndrome associated with neuroendocrine tumors [3] - The company is also developing atumelnant, an oral ACTH antagonist for congenital adrenal hyperplasia and Cushing's disease, along with other drug candidates targeting various endocrine conditions [3]